https://www.selleckchem.com/ph....armacological_epigen
uture marker for CAD in T2DM patients and its antagonists could be useful in the management of these patients. Patients with T2DM have significantly higher levels of serum iNOS and lower levels of eNOS. However, iNOS levels were significantly higher in T2DM patients with concomitant CAD. Moreover, iNOS activity positively correlated with glycemic control and hsCRP. Therefore, iNOS could be an emerging future marker for CAD in T2DM patients and its antagonists could be useful in the management of these patients. This study aim
Like
Comment
Share
